Y. Y. Cheng, L. Huang, K. M. Lee, K. Li, and S. M. Kumta, Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines, Pediatr Blood Cancer, vol.42, pp.410-415, 2004.

O. Fromigue, Z. Hamidouche, and P. J. Marie, Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion, J Biol Chem, vol.283, pp.30549-30556, 2008.

Z. F. Xin, Y. K. Kim, and J. St, Risedronate inhibits human osteosarcoma cell invasion, J Exp Clin Cancer Res, vol.28, p.105, 2009.

A. F. Foukas, N. S. Deshmukh, R. J. Grimer, D. C. Mangham, E. G. Mangos et al., Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells, J Bone Joint Surg Br, vol.84, pp.706-711, 2002.

Q. Zhou, Y. Zhu, Z. Deng, H. Long, S. Zhang et al., VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma, Surg Oncol, vol.20, pp.13-19, 2011.

J. Folkman and . Angiogenesis, Annu Rev Med, vol.57, pp.1-18, 2006.

J. Yang, D. Yang, Y. Sun, B. Sun, G. Wang et al., Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma, Cancer, vol.117, pp.4925-4938, 2011.

J. Lammli, M. Fan, H. G. Rosenthal, M. Patni, E. Rinehart et al., Expression of vascular endothelial growth factor correlates with the advance of clinical osteosarcoma, Int Orthop, vol.36, pp.2307-2313, 2012.

Y. H. Lee, T. Tokunaga, Y. Oshika, R. Suto, K. Yanagisawa et al., Cellretained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma, Eur J Cancer, vol.35, pp.1089-1093, 1999.

M. Kaya, T. Wada, T. Akatsuka, S. Kawaguchi, S. Nagoya et al., Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis, Clin Cancer Res, vol.6, pp.572-577, 2000.

H. Hara, T. Akisue, T. Fujimoto, M. Imabori, T. Kawamoto et al., Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors, Anticancer Res, vol.26, pp.4307-4311, 2006.

S. Dubois and G. Demetri, Markers of angiogenesis and clinical features in patients with sarcoma, Cancer, vol.109, pp.813-819, 2007.

S. Rastogi, R. Kumar, S. R. Sankineani, K. Marimuthu, L. Rijal et al., Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study, Int Orthop, vol.36, pp.2315-2321, 2012.

D. Chen, Y. J. Zhang, K. W. Zhu, and W. C. Wang, A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma, Tumour Biol, vol.34, pp.1895-1899, 2013.

M. Kreuter, R. Bieker, S. S. Bielack, T. Auras, H. Buerger et al., Prognostic relevance of increased angiogenesis in osteosarcoma, Clin Cancer Res, vol.10, pp.8531-8537, 2004.

L. F. Lau, CCN1/CYR61: the very model of a modern matricellular protein, Cell Mol Life Sci, vol.68, pp.3149-3163, 2011.

S. J. Leu, S. C. Lam, and L. F. Lau, Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells, J Biol Chem, vol.277, pp.46248-46255, 2002.

N. Chen, S. J. Leu, V. Todorovic, S. C. Lam, and L. F. Lau, Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells, J Biol Chem, vol.279, pp.44166-44176, 2004.

F. E. Mo, A. G. Muntean, C. C. Chen, D. B. Stolz, S. C. Watkins et al., CYR61 (CCN1) is essential for placental development and vascular integrity, Mol Cell Biol, vol.22, pp.8709-8720, 2002.

A. M. Babic, M. L. Kireeva, T. V. Kolesnikova, and L. F. Lau, CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth, Proc Natl Acad Sci, vol.95, pp.6355-6360, 1998.

J. A. Menéndez, I. Mehmi, D. W. Griggs, and R. Lupu, The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives, Endocr Relat Cancer, vol.10, pp.141-152, 2003.

W. G. Jiang, G. Watkins, O. Fodstad, D. , A. Mokbel et al., Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer, Endocr Relat Cancer, vol.11, pp.781-791, 2004.

Z. J. Sun, Y. Wang, Z. Cai, P. P. Chen, X. J. Tong et al., Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells, Br J Cancer, vol.99, pp.1656-1667, 2008.

O. Fromigue, Z. Hamidouche, P. Vaudin, F. Lecanda, A. Patino et al., CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis, J Bone Miner Res, vol.26, pp.1533-1542, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00626140

A. A. Sabile, M. J. Arlt, R. Muff, B. Bode, B. Langsam et al., Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice, J Bone Miner Res, vol.27, pp.58-67, 2012.

L. Wang, Q. Zhang, W. Chen, B. Shan, Y. Ding et al., B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis, PLoS ONE, vol.8, p.70689, 2013.

X. Wen, H. Liu, K. Yu, and Y. Liu, Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis, Tumour Biol, vol.35, pp.845-848, 2014.

M. D. Sternlicht and Z. Werb, How matrix metalloproteinases regulate cell behavior, Annu Rev Cell Dev Biol, vol.17, pp.463-516, 2001.

Y. Oda, H. Yamamoto, S. Tamiya, S. Matsuda, K. Tanaka et al., CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis, Mod Pathol, vol.19, pp.738-745, 2006.

Y. Pignochino, G. Grignani, G. Cavalloni, M. Motta, M. Tapparo et al., Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways, Mol Cancer, vol.8, p.118, 2009.

C. T. Wang, C. S. Lin, C. W. Shiau, P. Y. Chu, C. C. Hsiao et al., SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells, J Orthop Res, vol.31, pp.335-342, 2013.

G. Grignani, E. Palmerini, P. Dileo, S. D. Asaftei, D. 'ambrosio et al., A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study, Ann Oncol, vol.23, pp.508-516, 2012.

L. Wagner, B. Turpin, R. Nagarajan, B. Weiss, T. Cripe et al., Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors, Pediatr Blood Cancer, vol.60, pp.1447-1451, 2013.

A. N. Athanasopoulos, D. Schneider, T. Keiper, V. Alt, U. R. Pendurthi et al., Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in osteoblasts mediates proangiogenic activities in endothelial cells and promotes fracture healing, J Biol Chem, vol.282, pp.26746-26753, 2007.

I. V. Babkina, D. A. Osipov, Y. N. Solovyov, I. V. Bulycheva, G. N. Machak et al.,

. Endostatin, placental growth factor, and fibroblast growth factors-1 and -2 in the sera of patients with primary osteosarcomas, Bull Exp Biol Med, vol.148, pp.246-249, 2009.

C. Li, C. Zhan, Y. Chen, Q. Fu, X. D. Zhu et al., Analysis report for osteosarcoma expression profile, Eur Rev Med Pharmacol Sci, vol.17, pp.2804-2809, 2013.

T. Ren, Y. Qing, N. Dai, M. Li, C. Qian et al., Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells, Cancer Sci, vol.105, pp.186-194, 2014.

H. Odagiri, T. Kadomatsu, M. Endo, T. Masuda, M. S. Morioka et al., The secreted protein ANGPTL2 promotes metastasis of osteosarcoma cells through integrin ?5?1, p38 MAPK, and matrix metalloproteinases, Sci Signal, vol.7, p.7, 2014.

M. B. Mintz, R. Sowers, K. M. Brown, S. C. Hilmer, B. Mazza et al., An expression signature classifies chemotherapy-resistant pediatric osteosarcoma, Cancer Res, vol.65, pp.1748-1754, 2005.

J. M. Maris, J. Courtright, P. J. Houghton, C. L. Morton, R. Gorlick et al., Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program, Pediatr Blood Cancer, vol.50, pp.581-587, 2008.

M. L. Kireeva, S. C. Lam, and L. F. Lau, Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphav-beta3, J Biol Chem, vol.273, pp.3090-3096, 1998.

J. A. Menendez, L. Vellon, I. Mehmi, P. K. Teng, D. W. Griggs et al., A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway, Oncogene, vol.24, pp.761-779, 2005.

T. V. Byzova, C. K. Goldman, N. Pampori, K. A. Thomas, A. Bett et al., A mechanism for modulation of cellular responses to VEGF: activation of the integrins, Mol Cell, vol.6, pp.851-860, 2000.

J. L. Wilkinson-berka, D. Jones, G. Taylor, K. Jaworski, D. J. Kelly et al., SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity, Invest Ophthalmol Vis Sci, vol.47, pp.1600-1605, 2006.

R. Tsou and F. F. Isik, Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells, Mol Cell Biochem, vol.224, pp.81-89, 2001.

Y. Huang, Z. Lin, J. Zhuang, Y. Chen, and J. Lin, Prognostic significance of alpha V integrin and VEGF in osteosarcoma after chemotherapy, Onkologie, vol.31, pp.535-540, 2008.

N. Gomes, C. Legrand, and F. Fauvel-lafève, Shear stress induced release of von Willebrand factor and thrombospondin-1 in HUVEC extracellular matrix enhances breast tumour cell adhesion, Clin Exp Metastasis, vol.22, pp.215-223, 2005.

S. North, M. Moenner, and A. Bikfalvi, Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors, Cancer Lett, vol.218, pp.1-14, 2005.

R. Estrada, N. Li, H. Sarojini, A. J. Lee, M. J. Wang et al., Secretome from mesenchymal stem cells induces angiogenesis via Cyr61, J Cell Physiol, vol.219, pp.563-571, 2009.

R. Meyuhas, E. Pikarsky, E. Tavor, A. Klar, R. Abramovitch et al., A Key role for cyclic AMP-responsive element binding protein in hypoxia-mediated activation of the angiogenesis factor CCN1 (CYR61) in tumor cells, Mol Cancer Res, vol.6, pp.1397-1409, 2008.

M. Vilalta, I. R. Dégano, J. Bagó, D. Gould, M. Santos et al., Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity noninvasive bioluminescence imaging, Stem Cells Dev, vol.17, pp.993-1003, 2008.

I. Román, M. Vilalta, J. Rodriguez, A. M. Matthies, S. Srouji et al., Analysis of progenitor cell-scaffold combinations by in vivo non-invasive photonic imaging, Biomaterials, vol.28, pp.2718-2728, 2007.